In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advanced Tissue Sciences

This article was originally published in The Gray Sheet

Executive Summary

Firm announces submission of a premarket approval application to FDA for its Dermagraft wound dressing to treat diabetic foot ulcers. Clinical trials for the Dermagraft, which will be marketed by Smith & Nephew, indicate that the product heals significantly more ulcers than control treatment, the firm says in an Aug. 25 release. Competitor Organogenesis received an approvable recommendation from FDA's General and Plastic Surgery Devices panel in May (1"The Gray Sheet" May 15, 2000, p. 8)

You may also be interested in...



Revised Organogenesis/Novartis Deal Ensures Sure-Footing For Vitrix Trials

Organogenesis plans to enter pivotal clinical trials for its Vitrix living dermal replacement for deep diabetic foot ulcers this spring after amending a 1996 exclusive marketing agreement with Novartis covering Apligraf, announced Feb. 26.

Revised Organogenesis/Novartis Deal Ensures Sure-Footing For Vitrix Trials

Organogenesis plans to enter pivotal clinical trials for its Vitrix living dermal replacement for deep diabetic foot ulcers this spring after amending a 1996 exclusive marketing agreement with Novartis covering Apligraf, announced Feb. 26.

Advanced Tissue Sciences

FDA requests clarification and additional information from ATS regarding its premarket approval application for Dermagraft for the treatment of diabetic foot ulcers, according to a Feb. 21 company release. The PMA was submitted in August 2000. Upon approval, Dermagraft will be marketed by Smith & Nephew (1"The Gray Sheet" Aug. 28, 2000, In Brief)

Related Content

UsernamePublicRestriction

Register

MT013774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel